See more : International Silver, Inc. (ISLV) Income Statement Analysis – Financial Results
Complete financial analysis of Ambrx Biopharma Inc. (AMAM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ambrx Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- TIM S.A. (TIMB) Income Statement Analysis – Financial Results
- Kiwi Property Group Limited (KPG.NZ) Income Statement Analysis – Financial Results
- China Kings Resources Group Co.,Ltd. (603505.SS) Income Statement Analysis – Financial Results
- CellSeed Inc. (7776.T) Income Statement Analysis – Financial Results
- ItoKuro Inc. (6049.T) Income Statement Analysis – Financial Results
Ambrx Biopharma Inc. (AMAM)
About Ambrx Biopharma Inc.
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 7.40M | 7.46M | 13.67M | 10.31M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.40M | 7.46M | 13.67M | 10.31M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 53.31M | 54.81M | 20.43M | 26.38M |
| General & Administrative | 20.33M | 17.07M | 6.35M | 6.40M |
| Selling & Marketing | 2.73M | 0.00 | 0.00 | 0.00 |
| SG&A | 23.05M | 17.07M | 6.35M | 6.40M |
| Other Expenses | -2.22M | -3.86M | -4.75M | -38.00K |
| Operating Expenses | 74.14M | 71.88M | 26.79M | 32.78M |
| Cost & Expenses | -83.83M | 71.88M | 26.79M | 32.78M |
| Interest Income | 369.00K | 0.00 | 27.00K | 195.00K |
| Interest Expense | 968.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.29M | 2.15M | 1.94M | 2.05M |
| EBITDA | -55.79M | -62.27M | -11.17M | -20.42M |
| EBITDA Ratio | -753.69% | -835.28% | -81.72% | -198.03% |
| Operating Income | -57.08M | -64.42M | -13.12M | -22.47M |
| Operating Income Ratio | -771.16% | -864.17% | -95.93% | -217.94% |
| Total Other Income/Expenses | -18.98M | -3.86M | -4.72M | 157.00K |
| Income Before Tax | -76.06M | -68.29M | -17.84M | -22.32M |
| Income Before Tax Ratio | -1,027.55% | -915.99% | -130.48% | -216.42% |
| Income Tax Expense | 1.94M | 1.00K | 1.00K | -2.00K |
| Net Income | -78.00M | -68.29M | -17.84M | -22.31M |
| Net Income Ratio | -1,053.72% | -916.00% | -130.49% | -216.40% |
| EPS | -2.02 | -3.34 | -0.47 | -0.59 |
| EPS Diluted | -2.02 | -3.34 | -0.47 | -0.59 |
| Weighted Avg Shares Out | 38.61M | 20.45M | 37.67M | 37.67M |
| Weighted Avg Shares Out (Dil) | 38.61M | 20.45M | 37.67M | 37.67M |
Ambrx Announces Sale to Johnson & Johnson
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
The underdogs of 2023: Small-cap stocks that made it big
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Data
Ambrx Biopharma: Potential With Recently Released Prostate Cancer Data
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments
Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress
Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023
Source: https://incomestatements.info
Category: Stock Reports